Heart Failure With Reduced Ejection FractionNCT07283666
Subspecialty Ambulatory Quality Cardiology Program
An observational study of Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation, run by NYU Langone Health at 1 site in United States.
Trial summary
Investigators will evaluate the effectiveness of an audit and feedback performance improvement strategy in which cardiology providers receive quarterly emails on ambulatory quality improvement goals. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation
- How many people
- 7,000 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Dec 2024to 1 Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients seen by a cardiology provider in the ambulatory setting.
Who may be able to join
- Active diagnosis of atrial fibrillation
- CHADS2VASC of at least 2 in males and at least 3 in females
- Outpatient cardiology visit in past 3 months
- Most recent EF ≤40
- Age 18-90
- Outpatient cardiology visit in past 3 months
Who cannot join
- LAAO device
- Hemorrhagic Stroke
- SBP<90
- eGFR<30
- Potassium>5
- Active allergy to MRA
Show all 9Show fewer
- Acknowledge reason on heart failure alert
- Mechanical circulatory device
- Cardiac amyloid diagnosis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Subspecialty Ambulatory Quality Cardiology Program: An Audit and Feedback Performance Improvement Strategy
Investigators will evaluate the effectiveness of an audit and feedback performance improvement strategy in which cardiology providers receive quarterly emails on ambulatory quality improvement goals.
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Quarterly Emails | Quarterly emails on performance will be sent. | |
| Control | Usual Care (no emails on performance). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients eligible for medications who are prescribed these medications
Measured: Day 1
Secondary outcomes (2)
Percentage of patients with HFrEF prescribed aldosterone antagonists
Measured: Day 1
Percentage of patients with Afib prescribed oral anticoagulants
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start19 Dec 2024
- Primary completion1 Apr 2026 (estimated)
- Study completion1 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart Failure With Reduced Ejection FractionStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 7,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Amrita Mukhopadhyay, MD, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07283666
- Sponsor's protocol ID
- QI-Specialty Ambulatory
- Status last verified
- Dec 2025
- First submitted
- 4 Dec 2025
- Last updated
- 16 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is a quality improvement (QI) project and individual participant data (IPD) will not be shared with other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Subspecialty Ambulatory Quality Cardiology Program: An Audit and Feedback Performance Improvement Strategy
- ClinicalTrials.gov ID
- NCT07283666
- Acronym / sponsor ID
- QI-Specialty Ambulatory
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 7,000 participants (estimated)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Study start
- 19 Dec 2024 (actual)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 1 Jul 2026 (estimated)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigators will evaluate the effectiveness of an audit and feedback performance improvement strategy in which cardiology providers receive quarterly emails on ambulatory quality improvement goals.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Quarterly Emails | – | –Quarterly emails on performance will be sent. |
| Control | – | –Usual Care (no emails on performance). |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients seen by a cardiology provider in the ambulatory setting.
Key inclusion criteria (6 listed)
- Active diagnosis of atrial fibrillation
- CHADS2VASC of at least 2 in males and at least 3 in females
- Outpatient cardiology visit in past 3 months
- Most recent EF ≤40
- Age 18-90
Key exclusion criteria (9 listed)
- LAAO device
- Hemorrhagic Stroke
- SBP<90
- eGFR<30
- Potassium>5
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of patients eligible for medications who are prescribed these medications
Time frame: Day 1
2 secondary outcomes
Percentage of patients with HFrEF prescribed aldosterone antagonists
Time frame: Day 1
Percentage of patients with Afib prescribed oral anticoagulants
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2025.
- Individual participant dataSharing planned: No. This is a quality improvement (QI) project and individual participant data (IPD) will not be shared with other researchers.
Related trials for Heart Failure With Reduced Ejection Fraction
Recruiting
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
Mitral Regurgitation Functional, Heart Failure With Reduced Ejection Fraction (HFrEF)
Not yet recruitingObservational study
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure
Not yet recruitingObservational study
Metabolic Changes in Heart Failure Patients Treated With Vericiguat
Heart Failure, Worsening Heart Failure
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Recruiting
Evaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amrita Mukhopadhyay, MD principal investigator
NYU Langone Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation, run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 16 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients eligible for medications who are prescribed these medications (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2025.